<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:department>Leeds Institute of Molecular Medicine</gtr:department><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3545CDC8-076D-4BD8-B370-8E558F9D46EE"><gtr:id>3545CDC8-076D-4BD8-B370-8E558F9D46EE</gtr:id><gtr:name>Leeds Teaching Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Beckett Street</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS9 7TF</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E0FE17FA-1DD6-43B8-A42A-F07867156D72"><gtr:id>E0FE17FA-1DD6-43B8-A42A-F07867156D72</gtr:id><gtr:firstName>Matthew</gtr:firstName><gtr:otherNames>P</gtr:otherNames><gtr:surname>Welberry Smith</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701382"><gtr:id>C450A957-9885-4E43-AD9D-1E5364BC07AF</gtr:id><gtr:title>Proteomic identification and validation of novel biomarkers for monitoring the early phase of renal transplantation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0701382</gtr:grantReference><gtr:abstractText>The number of people being diagnosed with kidney failure is increasing. The treatments for the most severe forms when the kidneys fail completely are dialysis or a kidney transplant. Transplantation is associated with a better quality of life, greater survival, and is cheaper, saving the NHS more than &amp;pound;490 million per year. However, transplanted kidneys don?t always work immediately, or they may be rejected. The most common way of finding out that there is a problem is by measuring levels of a substance (creatinine) in the blood and then taking a small piece (biopsy) of the kidney tissue but this has risks, is unpleasant for the patient and may be done too late when too much damage has happened. This project is aimed at finding better biomarkers, that is substances (proteins) which can be measured in a blood or urine sample and give us earlier information about whether the kidney is working properly, and if it isn?t, help us decide quickly what is going wrong. This would enable us to treat the patient in the best way and prevent loss or misfunctioning of the transplanted kidney, both in the short and longer term.</gtr:abstractText><gtr:technicalSummary>Aims: To identify and validate potential biomarkers for important complications in the early phase after renal transplantation, focusing particularly on delayed graft function (DGF) and acute rejection (AR).

Specific objectives: 1)To use proteomic approach(es) to identify candidate diagnostic or prognostic biomarkers for AR, or DGF subtypes, using current serum banks and prospectively collected urine, plasma, and transplant perfusates; 2)To validate and assess their clinical utility in further independent prospective samples (including core biopsies); 3)To investigate findings of mechanistic relevance for potential targeting or increasing understanding of underlying pathogenesis.

Methodology and study design: An existing bank of serum samples collected serially following renal transplantation (n=258) will be used for the discovery phase with a proposed collection of serum, plasma, urine and archival tissue forming an independent validation set (urine and perfusate samples will also be used for discovery), with clinical data. Selected samples from 5 groups will form the main focus: DGF (AR or acute tubular necrosis) vs immediate graft function (no complications or AR or acute tubular necrosis). The complementary approaches of 2D-DIGE, SELDI and for a limited number of samples, nano-LC-MS/MS with 8-plex iTRAQ labelling will be used to compare samples longitudinally within patients and cross-sectionally between patient groups. Potentially discriminatory proteins or profiles will be identified, confirmed and validated in an independent test set - following development of single analyte or multiplex ELISAs or immuno-MS (depending on protein/peptide). Immunohistochemical analysis of the core biopsies will be used to examine protein expression/source. Potentially useful markers would ultimately be taken forward in long-term validation studies under the auspices of UKCRN and with the involvement of clinical assay companies. Selected markers which provide information of possible biological/mechanistic relevance would also be pursued further using suitable cell-based systems. 

Scientific and medical opportunities: The excellent improvements in patient health and long term outcomes made possible by renal transplantation can be forestalled by complications in the early post-transplant period. These include DGF and AR. Biomarkers which allow detection of these complications as early as possible, as well as differentiation between subtypes of DGF, would facilitate early treatment of these complications and so reduce their impact on both the patient and the transplant. This translational research project has the potential to deliver clinically useful biomarkers (potentially transferable to other forms of acute kidney injury), and may also provide new targets for intervention by providing mechanistic insight into the underlying pathogenesis.</gtr:technicalSummary><gtr:fund><gtr:end>2012-02-29</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>220751</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Article in Yorkshire Kidney Research Fund Newsletter</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>A028EABB-5803-4C2B-9135-3F74EB431EF8</gtr:id><gtr:impact>Article detailing the research for patients to read

N/A</gtr:impact><gtr:outcomeId>8E212581332</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>14480</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Yorkshire Kidney Research Fund</gtr:description><gtr:end>2012-02-02</gtr:end><gtr:fundingOrg>Yorkshire Kidney Research Fund</gtr:fundingOrg><gtr:id>5119AA86-A109-45DB-9458-CBF20EEA0CB4</gtr:id><gtr:outcomeId>YcuGG8mNWcF0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Measurement of ACY-1 by ELISA in human serum in ischaemia reperfusion injury, specifically in Delayed Graft Function after renal transplantation</gtr:description><gtr:grantRef>G0701382</gtr:grantRef><gtr:id>2E192C10-C65C-47B2-ADEF-0F18E6EC61B8</gtr:id><gtr:impact>N/A</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>eoyJN3gYhVV</gtr:outcomeId><gtr:patentId>1211229.8</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Aminocylase-1 as a novel biomarker in delayed graft function after renal transplantation</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C555C42C-619F-43F7-9DA7-C003D5489878</gtr:id><gtr:title>A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses.</gtr:title><gtr:parentPublicationTitle>Proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4483f1a162474c6556fc9d1b19223f5"><gtr:id>f4483f1a162474c6556fc9d1b19223f5</gtr:id><gtr:otherNames>Smith MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1615-9853</gtr:issn><gtr:outcomeId>PnuGMSS4BnR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3E93F0F-CC4E-44D1-A6EB-BE20E9E70A03</gtr:id><gtr:title>Application of proteomic analysis to the study of renal diseases.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4483f1a162474c6556fc9d1b19223f5"><gtr:id>f4483f1a162474c6556fc9d1b19223f5</gtr:id><gtr:otherNames>Smith MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1759-5061</gtr:issn><gtr:outcomeId>2241D49385C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B129BE5F-2CA6-4926-B869-5DAA16FF4DF7</gtr:id><gtr:title>Serum aminoacylase-1 is a novel biomarker with potential prognostic utility for long-term outcome in patients with delayed graft function following renal transplantation.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bcbaa39c82b31a9cad4f3a425b4610dd"><gtr:id>bcbaa39c82b31a9cad4f3a425b4610dd</gtr:id><gtr:otherNames>Welberry Smith MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>pm_16213_23_23739232</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701382</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>2EEE0958-6BE1-4D16-B86B-5D954CD37219</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Renal and Urogenital</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>